The Influence of Gut Microbial Species on Diabetes Mellitus

被引:7
作者
AL-Ishaq, Raghad Khalid [1 ]
Samuel, Samson Mathews [1 ]
Busselberg, Dietrich [1 ]
机构
[1] Qatar Fdn, Dept Physiol & Biophys, Weill Cornell Med Qatar, Doha 24144, Qatar
关键词
Bifidobacterium adolescentis; Bifidobacterium bifidum; diabetes; gut; Lactobacillus rhamnosus; microbiome; LACTOBACILLUS-RHAMNOSUS GG; METABOLIC ENDOTOXEMIA; TYPE-2; METFORMIN; METAANALYSIS; OBESITY;
D O I
10.3390/ijms24098118
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetes mellitus (DM) is a metabolic disorder with an alarming incidence rate and a considerable burden on the patient's life and health care providers. An increase in blood glucose level and insulin resistance characterizes it. Internal and external factors such as urbanization, obesity, and genetic mutations could increase the risk of DM. Microbes in the gut influence overall health through immunity and nutrition. Recently, more studies have been conducted to evaluate and estimate the role of the gut microbiome in diabetes development, progression, and management. This review summarizes the current knowledge addressing three main bacterial species: Bifidobacterium adolescentis, Bifidobacterium bifidum, and Lactobacillus rhamnosus and their influence on diabetes and its underlying molecular mechanisms. Most studies illustrate that using those bacterial species positively reduces blood glucose levels and activates inflammatory markers. Additionally, we reported the relationship between those bacterial species and metformin, one of the commonly used antidiabetic drugs. Overall, more research is needed to understand the influence of the gut microbiome on the development of diabetes. Furthermore, more efforts are required to standardize the model used, concentration ranges, and interpretation tools to advance the field further.
引用
收藏
页数:16
相关论文
共 85 条
  • [1] Metformin: an old but still the best treatment for type 2 diabetes
    Aguayo Rojas, Lilian Beatriz
    Gomes, Marilia Brito
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2013, 5
  • [2] The Gut Microbiota and Inflammation: An Overview
    Al Bander, Zahraa
    Nitert, Marloes Dekker
    Mousa, Aya
    Naderpoor, Negar
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (20) : 1 - 22
  • [3] Al-Ishaq R.K., 2020, CANCERS, V14, DOI [10.3390/cancers14246073, DOI 10.3390/CANCERS14246073]
  • [4] Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer
    AL-Ishaq, Raghad Khalid
    Koklesova, Lenka
    Kubatka, Peter
    Busselberg, Dietrich
    [J]. CANCERS, 2022, 14 (09)
  • [5] Enzymatic Metabolism of Flavonoids by Gut Microbiota and Its Impact on Gastrointestinal Cancer
    AL-Ishaq, Raghad Khalid
    Liskova, Alena
    Kubatka, Peter
    Busselberg, Dietrich
    [J]. CANCERS, 2021, 13 (16)
  • [6] Phytochemicals and Gastrointestinal Cancer: Cellular Mechanisms and Effects to Change Cancer Progression
    AL-Ishaq, Raghad Khalid
    Overy, Anthony J.
    Buesselberg, Dietrich
    [J]. BIOMOLECULES, 2020, 10 (01)
  • [7] Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels
    AL-Ishaq, Raghad Khalid
    Abotaleb, Mariam
    Kubatka, Peter
    Kajo, Karol
    Busselberg, Dietrich
    [J]. BIOMOLECULES, 2019, 9 (09)
  • [8] Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment
    Amar, Jacques
    Chabo, Chantal
    Waget, Aurelie
    Klopp, Pascale
    Vachoux, Christelle
    Bermudez-Humaran, Luis G.
    Smirnova, Natalia
    Berge, Mathieu
    Sulpice, Thierry
    Lahtinen, Sampo
    Ouwehand, Arthur
    Langella, Philippe
    Rautonen, Nina
    Sansonetti, Philippe J.
    Burcelin, Remy
    [J]. EMBO MOLECULAR MEDICINE, 2011, 3 (09) : 559 - 572
  • [9] [Anonymous], 2017, Diabetes
  • [10] Banday Mujeeb Z, 2020, Avicenna J Med, V10, P174, DOI 10.4103/ajm.ajm_53_20